Patients with fibromyalgia in Finnish healthcare center: one-year follow up
Järvinen, Tommi; Varinen, Aleksi; Sumanen, Markku (2023-09)
Avaa tiedosto
Lataukset:
Järvinen, Tommi
Varinen, Aleksi
Sumanen, Markku
09 / 2023
Scandinavian Journal of Primary Health Care
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202311109568
https://urn.fi/URN:NBN:fi:tuni-202311109568
Kuvaus
Peer reviewed
Tiivistelmä
Objectives: The study aimed to find whether Örebro Musculoskeletal Pain Screening Questionnaire (ÖMPSQ) predicts the severity of fibromyalgia symptoms after one year in patients with fibromyalgia. The second aim of the study was to observe how symptoms evolved during a one-year follow-up.
Design: Prospective cohort and observational study. Five questionnaires were sent to patients. The same questionnaires (excluding ÖMPSQ) were sent after one year. The patients were allocated into two cohorts using the results of ÖMPSQ. Other variables were analyzed and observed separately.
Setting: Primary healthcare center in the city of Nokia, Pirkanmaa, Finland
Subjects: Patients with fibromyalgia were included in the study after a physician’s examination and confirmation of diagnosis with the assistance of the American College of Rheumatology (ACR) 2010 criteria.
Main outcome measures: Fibromyalgia impact questionnaire (FIQ) scores
Results: The FIQ scores increased slightly in both ÖMPSQ-cohorts with no statistically significant differences. The patients mostly reported that the symptoms were unchanged or got worse when asked separately from other questionnaires. There was a statistically significant decrease in PHQ-9 score in depressed patients who received antidepressants and/or psychological therapy. In addition, FIQ scores also decreased in depressed patients. Patients who received alterations to the treatment plan reported positive changes in the symptoms more often.
Conclusion: With these results, we cannot conclude that ÖMPSQ predicts the patient’s severity of symptoms. On the contrary, we can conclude that antidepressants and/or psychological therapy might reduce fibromyalgia symptoms for depressed patients with fibromyalgia. Patients with fibromyalgia might benefit from clinical evaluation and modifications to the treatment plan
if necessary.
Design: Prospective cohort and observational study. Five questionnaires were sent to patients. The same questionnaires (excluding ÖMPSQ) were sent after one year. The patients were allocated into two cohorts using the results of ÖMPSQ. Other variables were analyzed and observed separately.
Setting: Primary healthcare center in the city of Nokia, Pirkanmaa, Finland
Subjects: Patients with fibromyalgia were included in the study after a physician’s examination and confirmation of diagnosis with the assistance of the American College of Rheumatology (ACR) 2010 criteria.
Main outcome measures: Fibromyalgia impact questionnaire (FIQ) scores
Results: The FIQ scores increased slightly in both ÖMPSQ-cohorts with no statistically significant differences. The patients mostly reported that the symptoms were unchanged or got worse when asked separately from other questionnaires. There was a statistically significant decrease in PHQ-9 score in depressed patients who received antidepressants and/or psychological therapy. In addition, FIQ scores also decreased in depressed patients. Patients who received alterations to the treatment plan reported positive changes in the symptoms more often.
Conclusion: With these results, we cannot conclude that ÖMPSQ predicts the patient’s severity of symptoms. On the contrary, we can conclude that antidepressants and/or psychological therapy might reduce fibromyalgia symptoms for depressed patients with fibromyalgia. Patients with fibromyalgia might benefit from clinical evaluation and modifications to the treatment plan
if necessary.
Kokoelmat
- TUNICRIS-julkaisut [19313]